Long-term Efficacy and Safety of Recombinant Interferon Alpha-2 vs. Hydroxyurea in Polycythemia Vera: Preliminary Results From the Three-Year Analysis of the DALIAH Trial – A Randomized Controlled Phase III Clinical Trial.

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weiss Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben Kruse, Hans Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer LarsenHans Carl Hasselbalch, Hans Carl Hasselbalch

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearchpeer-review

Original languageEnglish
Publication date3. Dec 2018
Publication statusPublished - 3. Dec 2018
EventAmerican Society of Hematology: 60th Annual Meeting (ASH) - San Diego, United States
Duration: 29. Nov 20184. Dec 2018

Conference

ConferenceAmerican Society of Hematology: 60th Annual Meeting (ASH)
CountryUnited States
CitySan Diego
Period29/11/201804/12/2018

Cite this

Knudsen, T. A., Lund Hansen, D., Ocias, L. F., Weiss Bjerrum, O., Brabrand, M., El Fassi, D., Frederiksen, M., Kjær, L., Kielsgaard Kristensen, T., Kruse, T., Mourits-Andersen, H. T., Møller, P., Overgaard, U. M., Severinsen, M. T., Skov, V., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., ... Hasselbalch, H. C. (2018). Long-term Efficacy and Safety of Recombinant Interferon Alpha-2 vs. Hydroxyurea in Polycythemia Vera: Preliminary Results From the Three-Year Analysis of the DALIAH Trial – A Randomized Controlled Phase III Clinical Trial.. Abstract from American Society of Hematology: 60th Annual Meeting (ASH), San Diego, United States.